Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andrea K. Kukla"'
Autor:
Avudaiappan Chokkalingam, Aaron. R. Mangold, Jenna. E. Murray, Kelly. D. Avery, Naveen. L. Pereira, Andrea. K. Kukla, Michelle. D. Monosmith
Publikováno v:
Journal of Clinical and Translational Science, Vol 8, Pp 152-152 (2024)
OBJECTIVES/GOALS: Mayo Clinic (MC) launched the Rapid Activation Trial (RAT) pilot program in 2022 to expedite the activation of high priority and high impact clinical trials. The objective was to develop a process for rapid activation through robust
Externí odkaz:
https://doaj.org/article/953bb9976ae44ab6a04cff677b4a16d9
Autor:
Jennifer A. Weis, Rachel Hardtke, Linda J. Sanders, Laura Nelle Hanson, Sharon Elcombe, Andrea K. Kukla, Sasa Andrijasevic
Publikováno v:
Journal of Clinical and Translational Science. 4:32-32
OBJECTIVES/GOALS: A workflow management tool is essential in order to help support consistent processes with transparency in next steps of the study process. Prior to this tool, staff has relied upon extensive training and coaching on the study proce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caed95175b3222e92079e77c1cd28aac
https://doi.org/10.1017/cts.2020.132
https://doi.org/10.1017/cts.2020.132
Autor:
Janice S. Grace, Julie T. Watters, John D. Myren, Andrea K. Kukla, Adil E. Bharucha, Gary C. Cseko, Pamela S. Kwon, Michael S. Lee, Jane C. Welter, Jennifer A. Weis, Rebecca S. Kottschade, Alissa R. Cornell, Linda J. Sanders, Michelle D. Monosmith, Marc N. Shaft, Virginia Nickie M. Bruce, Jason H. Pitzen
Publikováno v:
Clinical pharmacology and therapeutics. 103(1)
The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02328ab045ff43a1cfc2b9d77beadf39
https://pubmed.ncbi.nlm.nih.gov/29105757
https://pubmed.ncbi.nlm.nih.gov/29105757
Autor:
Wan-Teck Lim, Andrea K. Kukla, Nina J. Karlin, Julian R. Molina, Keith C. Bible, Vera J. Suman, Robert C. Smallridge, Charles Erlichman, Kevin P. Webster, Boon Cher Goh, Anne M. Traynor, Priya Kumar, Jill K. Burton, Pamela Jo Harris, Carolyn Bieber, Michael E. Menefee, Ayoko R. Bossou, William J. Maples, Crescent R. Isham
Publikováno v:
The Journal of clinical endocrinology and metabolism. 97(9)
Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).Preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28f9f3eab8ad4ce5eb62ea4875d0b56
https://pubmed.ncbi.nlm.nih.gov/22847238
https://pubmed.ncbi.nlm.nih.gov/22847238
Autor:
Prema P. Peethambaram, Leigh C. Gomez Dahl, Matthew P. Boente, L. Austin Doyle, John Wright, Viji Shridhar, Crescent R. Isham, Mathew J. Mauer, Andrea K. Kukla, Jennifer D. Tibodeau, Keith C. Bible, William J. Maples, Kalli J. Voll, David L. Groteluschen, Alexander D. Colevas, Jill K. Burton, Jacie L. Maguire, Ann L. Oberg, Charles Erlichman
Publikováno v:
Gynecologic oncology. 127(1)
Based upon promising preclinical and phase 1 trial results, combined flavopiridol and cisplatin therapy was evaluated in patients with ovarian and primary peritoneal cancers.A two cohort phase 2 trial of cisplatin (60 mg/m2 IV) immediately followed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b696b9d3a4c0564d346708d13517b3a
https://pubmed.ncbi.nlm.nih.gov/22664059
https://pubmed.ncbi.nlm.nih.gov/22664059
Autor:
Jill K. Burton, Crescent R. Isham, Kevin P. Webster, Ayoko R. Bossou, Pamela Jo Harris, Carolyn Bieber, Charles Erlichman, Priya Kumar, Wan-Teck Lim, VJ Suman, Keith C. Bible, Robert C. Smallridge, William J. Maples, Nina J. Karlin, Julian R. Molina, Anne M. Traynor, Andrea K. Kukla, Boon Cher Goh, Michael E. Menefee
Publikováno v:
Journal of Clinical Oncology. 30:5544-5544
5544 Background: Pazopanib, an orally bioavailable multitargeted inhibitor of kinases including VEGF-R, demonstrated impressive activity in metastatic differentiated thyroid cancer (49% durable RECIST PRs) and promising preclinical activity in anapla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a0aebd0649a1e8a2466c358f587bb74
https://doi.org/10.1200/jco.2012.30.15_suppl.5544
https://doi.org/10.1200/jco.2012.30.15_suppl.5544
Autor:
Keith Christopher Bible, Prema P. Peethambaram, Ann L. Oberg, William J. Maples, David L. Groteluschen, Matthew Boente, Jill K. Burton, Leigh C. Gomez-Dahl, Jennifer D. Tibodeau, Crescent R. Isham, Andrea K. Kukla, Kalli J. Voll, Alexander D. Colevas, John Wright, L Austin Doyle, Charles Erlichman, Mayo Phase Consortium
Publikováno v:
Cancer Research. 71:4712-4712
Background: Based upon preclinical synergy and prior phase 1 study results, the clinical efficacy of flavopiridol combined with cisplatin was assessed in patients with recurrent ovarian and primary peritoneal cancers. Methods: A two cohort phase 2 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3a0473141cf6f02b2f82109596cda08
https://doi.org/10.1158/1538-7445.am2011-4712
https://doi.org/10.1158/1538-7445.am2011-4712